Nicotinic antagonists

Ehave KetaDASH Subsidiary Commences Data Collection for Potential Patients and Partnering Clinics

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Drugs, Health sciences, Antidepressants, Arylcyclohexylamines, Ketones, Nicotinic antagonists, Sedatives, Ketamine, Therapy, Healthcare industry

b'MIAMI, May 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics.

Key Points: 
  • b'MIAMI, May 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics.
  • KetaDASH is available to ketamine clinics and qualified patients whose healthcare provider has prescribed it as a treatment.
  • The KetaDASH platform utilizes proprietary software developed by Ehave which allows patients and medical professionals to view detailed reports on the ketamine therapy\xe2\x80\x99s progress.
  • More information on KetaDASH is available at www.ketadash.com .\nKetamine therapy has turned out to be a life-changing alternative to antidepressants for many patients.

Lamar Odom Reborn: New Documentary Follows NBA Athlete's Journey to Beat Addiction and Anxiety Through the Use of Psychedelic Medicines

Retrieved on: 
Monday, May 17, 2021
Branches of biology, Psychoactive drugs, Drugs, NMDA receptor antagonists, Nicotinic antagonists, General anesthetics, Chloroarenes, Sedatives, Ketamine, Ibogaine, Odom, Post-traumatic stress disorder

Lamar admits he self-medicated and avoided professional interventions given the stigma attached with mental health treatment.\n"Admitting you are depressed or asking for help is a challenge for anyone," says Odom.

Key Points: 
  • Lamar admits he self-medicated and avoided professional interventions given the stigma attached with mental health treatment.\n"Admitting you are depressed or asking for help is a challenge for anyone," says Odom.
  • "My hope is that sharing my journey in Reborn will open a dialogue for millions of people.
  • Just months after my first ketamine and ibogaine treatments, I felt physically well enough to play professional basketball again.
  • "Ketamine, however, is an FDA-approved anesthetic that has been hailed as a miracle for treating depression, anxiety, PTSD, addiction, and more.

MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development

Retrieved on: 
Thursday, May 13, 2021
Psychoactive drugs, Entheogens, Drugs, Branches of biology, Drug rehabilitation, NMDA receptor antagonists, Nicotinic antagonists, Hallucinations, Ibogaine, Psychedelic drug, N,N-Dimethyltryptamine, 18-Methoxycoronaridine

b'NEW YORK, May 13, 2021 /PRNewswire/ --MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of Pharmaceutical Development.\nAs MindMed progresses it\'s Discover and Develop efforts for multiple commercial clinical programs including LSD and an ibogaine derivative, 18-MC, Peter will lead MindMed\'s product development activities across its entire portfolio of investigational drugs.

Key Points: 
  • b'NEW YORK, May 13, 2021 /PRNewswire/ --MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of Pharmaceutical Development.\nAs MindMed progresses it\'s Discover and Develop efforts for multiple commercial clinical programs including LSD and an ibogaine derivative, 18-MC, Peter will lead MindMed\'s product development activities across its entire portfolio of investigational drugs.
  • In addition, Peter will oversee partnerships with Contract Manufacturing Development Organizations and other discovery efforts to support the advancement of MindMed\'s proprietary new chemical entities.\nPeter joins MindMed from AstraZeneca, where he was the Director of Manufacturing for Inhalation Product Development.
  • Peter also holds a Masters of Science in Mechanical Engineering from MIT.
  • The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC.

Braxia Scientific Opens First Ketamine Therapy Clinic in Quebec; Enters Joint Venture with Neurotherapy Montreal, A Leading Brain Injury Solutions Clinic for Adults and Children

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Neuroscience, Clinical medicine, Neurotechnology, Neuropsychology, Antidepressants, Nicotinic antagonists, Sedatives, Ketamine, Nasal administration, Neurofeedback, Neuromodulation

"\nThe new clinic is located within Neurotherapy Montreal\'s state of the art 14,000 square foot facility providing leading mental health and rehabilitation services, more specifically, brain-based solutions for children and adults using the latest neuromodulation and neuroscience technologies.

Key Points: 
  • "\nThe new clinic is located within Neurotherapy Montreal\'s state of the art 14,000 square foot facility providing leading mental health and rehabilitation services, more specifically, brain-based solutions for children and adults using the latest neuromodulation and neuroscience technologies.
  • "Since opening our clinics less than 3 years ago, we have administered over 3,000 Intravenous Ketamine Infusionsand over 60 Intranasal Ketamine treatments.
  • Through Braxia Health clinics, these treatments have shown highly significant rapid-acting efficacy to patients with depression.
  • "\nThe clinic is to be operated as a joint venture, owned equally by the Company and NMC.

Delic's Acquisition Target, Ketamine Infusion Centers, Announces Proposal to Acquire 2 Additional Clinic Locations

Retrieved on: 
Tuesday, May 11, 2021
Psychoactive drugs, Drugs, Medical specialties, General anesthetics, Arylcyclohexylamines, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine, Post-traumatic stress disorder, KIC

("DELIC" or "the "Company") (CSE: DELC) (OTCQB: DELFC) a psychedelic wellness platform, is pleased to announce that its acquisition target (under binding letter agreement see news release dated February 4, 2021), Ketamine Infusion Centers ("KIC"), proposes to acquire two (2) additional licensed ketamine clinics in Arizona.

Key Points: 
  • ("DELIC" or "the "Company") (CSE: DELC) (OTCQB: DELFC) a psychedelic wellness platform, is pleased to announce that its acquisition target (under binding letter agreement see news release dated February 4, 2021), Ketamine Infusion Centers ("KIC"), proposes to acquire two (2) additional licensed ketamine clinics in Arizona.
  • "KIC is the leading name in high quality care and incredible outcomes for its patients and this move helps grow that reputation significantly.
  • As a vital part of the Delic platform, KIC will continue to offer wellness and benefits for many people suffering from anxiety, depression and PTSD.
  • Ketamine Infusion Centers unique model and passion to obtain the highest patient outcomes and purely evidence-based practices is a perfect fit in the Delic ecosystem.

Lyndra Therapeutics Receives FDA Clearance of Investigational New Drug Application for LYN-014, its Once-Weekly Oral Levomethadone Treatment in Development for Opioid Use Disorder

Retrieved on: 
Thursday, May 6, 2021
Biotechnology, Mental health, Health, Pharmaceutical, Clinical trials, Drug rehabilitation, Drugs, Ketones, Synthetic opioids, Chemistry, Psychoactive drugs, Euphoriants, Nicotinic antagonists, Levomethadone, Methadone, Opioid use disorder, Opioid

b'Lyndra Therapeutics , a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for LYN-014, the Company\xe2\x80\x99s oral, ultra-long-acting, extended-release (ER) levomethadone capsule in development for the weekly treatment of opioid use disorder.

Key Points: 
  • b'Lyndra Therapeutics , a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for LYN-014, the Company\xe2\x80\x99s oral, ultra-long-acting, extended-release (ER) levomethadone capsule in development for the weekly treatment of opioid use disorder.
  • The IND clearance enables Lyndra to initiate a Phase 1 clinical trial in patients currently taking and controlled on daily oral immediate release (IR) methadone.
  • Levomethadone is an enantiomer of racemic methadone approved for use in Europe since the 1960s for pain management and opioid maintenance therapy.
  • Results from the 2016 National Survey on Drug Use and Health: Detailed Tables.

Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration of Ketamine and Psychedelic Clinics and its Research and Development Priorities

Retrieved on: 
Monday, May 3, 2021
Drugs, Psychoactive drugs, Neurochemistry, Antidepressants, General anesthetics, Arylcyclohexylamines, Chloroarenes, Nicotinic antagonists, Ketamine, Forward-looking statement

The name change reflects the Company\'s commitment to providing access to, and leadership in, setting the standard of care for ketamine treatment in depression through its network of clinics, as well as the Company\'s ketamine and psychedelic derivative research and drug development priorities.

Key Points: 
  • The name change reflects the Company\'s commitment to providing access to, and leadership in, setting the standard of care for ketamine treatment in depression through its network of clinics, as well as the Company\'s ketamine and psychedelic derivative research and drug development priorities.
  • Our goal is to improve the access and quality of mental healthcare service to people affected by these disorders in a highly cost-effective manner.
  • All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements.
  • There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/champignon-brands-changes-name-t...\n'

Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021

Retrieved on: 
Saturday, May 1, 2021
Branches of biology, Drugs, Psychoactive drugs, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, General anesthetics, Nicotinic antagonists, NMDA receptor, Ketamine, N-Methyl-D-aspartic acid, Antidepressant

In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.

Key Points: 
  • In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.
  • The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation

Retrieved on: 
Thursday, April 29, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Dissociative drugs, Ketones, Nicotinic antagonists, Sedatives, Ketamine, United States patent law, Pain management, Patent

b'SANTA BARBARA, Calif., April 29, 2021 /PRNewswire/ -- Bexson Biomedical, Inc., aresearch-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat.

Key Points: 
  • b'SANTA BARBARA, Calif., April 29, 2021 /PRNewswire/ -- Bexson Biomedical, Inc., aresearch-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat.
  • 10,973,780, describing pharmaceutical formulations and treatment methods including the company\'s BB106 ketamine therapy.
  • This patent represents Bexson\'s first application of these innovations to enable a subcutaneous ketamine delivery platform designed for management of pain disorders and mental health conditions.
  • The patent process is a long road and we are pleased to see this first one be issued," said Gregg Peterson, Bexson co-founder and CEO.\nThe company is engaging FDA to prepare for clinical trials evaluating its patented ketamine formula delivered subcutaneously.

Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting

Retrieved on: 
Thursday, April 29, 2021
Branches of biology, Drugs, Psychoactive drugs, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, General anesthetics, Nicotinic antagonists, NMDA receptor, Ketamine, N-Methyl-D-aspartic acid, Antidepressant

In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.

Key Points: 
  • In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.
  • The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.